**Partnering Opportunities**

**TNFR2 Agonist Antibody Program (MM-401)**

- Exciting Immuno-oncology Drug Candidate Against Novel Immunotherapy Target with Opportunity to be First in Class

- Preclinical program with extensive best in class mechanism and preclinical data:
  - Agonistic mechanism of action provides unique efficacy & safety
    - Co-stimulatory activity via TNFR2 signaling induces proliferation and activation T cells *in vitro* and *in vivo*
    - Fcy receptor binding essential for activity, but does not lead to significant depletion of cells (e.g. Tregs)
  - Robust anti-tumor activity in preclinical models
    - Complete or significant responses in multiple mouse syngeneic and human PBMC and PDX tumor models as a monotherapy
    - Superior survival across multiple syngeneic models when combined with PD-1/PD-L1
    - Induction of long-term anti-tumor memory in mice, no tumor growth in re-challenge studies

- Development status:
  - Two lead agonist antibodies selected and ready for cell line development
  - Favorably toxicity profile compared to antibodies targeting other T cell receptors
  - Clinical opportunities as monotherapy and I/O combination therapy
  - Initial PD strategy developed for patient selection
  - Patent applications pending


**TRAIL DR4/DR5 Agonist Program (MM-201)**

- Preclinical program superior to first generation agonists with robust preclinical package
  - Stable protein molecule with long half life
  - Superior safety and efficacy and safety shown compared to other TRAIL molecules
  - Anti-tumor activity demonstrated in multiple CRC-PDX models, as a monotherapy and in synergistic combination with SoC drugs

- Development status:
  - Lead candidates with CMC characteristics
  - CRC and Sarcoma identified as initial indications from multiple preclinical studies, with prostate cancer and multiple myeloma data as well
  - Biomarker strategy investigated
  - Patent applications pending

For more info, please email: BusDev@merrimack.com